Network origin in Michael Saunders first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Michael Saunders via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| HERON THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| Colgate University | College/University | Undergraduate Degree | |
| INOVIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| The University of Virginia School of Medicine | College/University | Doctorate Degree | |
Elevar Therapeutics, Inc.
 Elevar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elevar Therapeutics, Inc. engages in the provision of biopharmaceutical services. It offers Rivoceranib, a small-molecule angiogenesis inhibitor in gastric cancer that use in the growth and proliferation in cancer cells. The company was founded by Sung Chul Kim and Soo Whan Choi in 2005 and is headquartered in Salt Lake City, UT. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pierian Biosciences LLC
 Pierian Biosciences LLC Medical/Nursing ServicesHealth Services Pierian Biosciences LLC operates as a diagnostic development and laboratory service company. It offers ChemoINTEL, a functional multi-parametric chemosensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumor cells; and ImmunoINTEL, a flow cytometry-based platform delivering phenotypic characterization and quantitative functional interrogation of tumor and immune populations within a tumor sample and relevant tissues. The company is headquartered in Franklin, TN. | Medical/Nursing Services | Corporate Officer/Principal | |
| COVANCE INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
OncoPep, Inc.
 OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Investment Managers | Corporate Officer/Principal | |
| University of Zimbabwe | College/University | Doctorate Degree | |
| King's College London | College/University | Graduate Degree | |
| Nottingham Trent University | College/University | Undergraduate Degree | |
| AMRYT PHARMA PLC | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
| United States | 9 |
| United Kingdom | 4 |
| Zimbabwe | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 6 |
| Commercial Services | 2 |
| Health Services | 2 |
| Finance | 2 |
Operational
| Corporate Officer/Principal | 6 |
| Chief Tech/Sci/R&D Officer | 5 |
| Undergraduate Degree | 3 |
| Doctorate Degree | 2 |
| Graduate Degree | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Mark Gelder | 9 |
| Meena Arora | 4 |
| Victor Moyo | 3 |
- Stock Market
- Insiders
- Michael Saunders
- Company connections
